Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leiomyosarcoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 129 Carcinoma, Renal Cell 31 Parkinson Disease 4, Autosomal Dominant Lewy Body 27 Neoplasms 25 Cholangiocarcinoma 24 Endometrial Neoplasms 16 Thyroid Neoplasms 15 Liver Neoplasms 15 Melanoma 13 Biliary Tract Neoplasms 12 Stomach Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Recurrence 8 Ovarian Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Neoplasm Metastasis 7 Breast Neoplasms 7 Uterine Cervical Neoplasms 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Transitional Cell 4 Carcinoma 4 Adenocarcinoma 4 Thyroid Carcinoma, Anaplastic 3 Thyroid Cancer, Papillary 3 Solid Tumors 3

Interventions

Doxorubicin 22 Gemcitabine 15 Trabectedin 11 Ifosfamide 11 Radiotherapy 10 Docetaxel 10 Dacarbazine 8 pazopanib 6 Temozolomide 4 Specimen Handling 4 Nivolumab 4 Biopsy 4 Sunitinib 3 Sorafenib 3 Filgrastim 3 pembrolizumab 2 pegfilgrastim 2 liposomal doxorubicin 2 eribulin 2 cixutumumab 2 cemiplimab 2 brostallicin 2 belinostat 2 avelumab 2 X-Rays 2 Surgical Procedures, Operative 2 Radiotherapy, Conformal 2 Radiation Dose Hypofractionation 2 Radiation 2 PTC596 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡